Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein
Catalog No: P53WT-HP002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and HMTEVVRRC peptide (accession: A0A140T913(HLA-A*02:01) & P61769(B2M) &HMTEVVRRC).
Product Details
- Molecular Aliases
- MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer is greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 8.1ng/ml determined by ELISA (QC Test).
Background
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.
References
- (1)Donnellan Z, Bossi G, Harper J, et al. ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing[J]. Journal for ImmunoTherapy of Cancer, 2015, 3(Suppl 2):P299.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.